prikaz prve stranice dokumenta Patofiziološko značenje autoantitijela u krvi bolesnika sa solidnim tumorima
  Download
PDF 624.59 KB
master's thesis
Patofiziološko značenje autoantitijela u krvi bolesnika sa solidnim tumorima
Zagreb: University of Zagreb, School of Medicine, 2015. urn:nbn:hr:105:306758
Mihaljević, Marija
University of Zagreb
School of Medicine
Department of Pathophysiology

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Mihaljević, M. (2015). Patofiziološko značenje autoantitijela u krvi bolesnika sa solidnim tumorima (Master's thesis). Zagreb: University of Zagreb, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:306758

Mihaljević, Marija. "Patofiziološko značenje autoantitijela u krvi bolesnika sa solidnim tumorima." Master's thesis, University of Zagreb, School of Medicine, 2015. https://urn.nsk.hr/urn:nbn:hr:105:306758

Mihaljević, Marija. "Patofiziološko značenje autoantitijela u krvi bolesnika sa solidnim tumorima." Master's thesis, University of Zagreb, School of Medicine, 2015. https://urn.nsk.hr/urn:nbn:hr:105:306758

Mihaljević, M. (2015). 'Patofiziološko značenje autoantitijela u krvi bolesnika sa solidnim tumorima', Master's thesis, University of Zagreb, School of Medicine, accessed 26 November 2024, https://urn.nsk.hr/urn:nbn:hr:105:306758

Mihaljević M. Patofiziološko značenje autoantitijela u krvi bolesnika sa solidnim tumorima [Master's thesis]. Zagreb: University of Zagreb, School of Medicine; 2015 [cited 2024 November 26] Available at: https://urn.nsk.hr/urn:nbn:hr:105:306758

M. Mihaljević, "Patofiziološko značenje autoantitijela u krvi bolesnika sa solidnim tumorima", Master's thesis, University of Zagreb, School of Medicine, Zagreb, 2015. Available at: https://urn.nsk.hr/urn:nbn:hr:105:306758

Metadata
TitlePatofiziološko značenje autoantitijela u krvi bolesnika sa solidnim tumorima
Title (english)Pathophysiological role of circulating autoantibodies in patients with solid tumors
AuthorMarija Mihaljević
MentorMaja Sirotković-Skerlev (mentor)
Committee memberDAMIR VRBANEC (predsjednik povjerenstva)
Committee memberJasenka Markeljević (član povjerenstva)
Committee memberMaja Sirotković-Skerlev (član povjerenstva)
GranterUniversity of Zagreb
School of Medicine
(Department of Pathophysiology)
Zagreb
Defense date and country2015-07-15, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Immunology
Abstract
Biomarker je bilo koja molekula koja uzrokuje promjenu fiziološkog stanja pojedinca na bolest,terapiju ili toksine. U tom pogledu, autoantitijela povezana s karcinomima su odlični kandidati za detektiranje karcinomskih biomarkera koji se pojavljuju kao reakcija imunološkog sustava na tumor. Stvaranje autoantitijela koja se pojavljuju prema autolognim karcinomskim antigenima nije statično i mjerljivo je različitim analizama. Autoantitijela su izrazito stabilna u humanom serumu i dugo perzistiraju nakon uklanjanja antigena. To je njihova izrazita prednost te se koriste kao potencijalni markeri u tjelesnim tekućinama za detekciju karcinomskih antigena. Za razliku od autoantitijela, karcinomski antigeni imaju kratko poluvrijeme raspada. Zbog toga, stabilnost autoantitijela je bitna u razvoju laboratorijskih testova. Glavna uloga pronalaska autoantitijela je u tome da se razlikuje fiziološko stanje od patološkog, prvenstveno u ranim asimptomatskim fazama karcinoma. Probir biomarkera mogao bi poboljšati dijagnostičku vrijednost medicinskog statusa, testova i ostalih procedura. Ostali testovi probira kao što su mamografija i kolonoskopija pomažu u pronalasku inicijalnih znakova karcinoma. Istraživanje autoantitijela je bitno da bi se utvrdila bolest u inicijalnoj fazi. U otkrivanju biomarkera su razvijene razne strategije. Osjetljivost i specifičnost testova mora biti dovoljno visoka da bi se autoantitijela upotrijebila za skrining. Potrebno je daljnje istraživanje autoantitijela i tehnika koja bi ih otkrivale. To bi moglo doprinijeti ranoj dijagnostici karcinoma i većem uspjehu terapije.
Abstract (english)
A bimarker is any molecule that indicates an alteration of the physiological state of an individual relevant to disease state, treatment and toxins. In this field, autoantibodies are beign considered as excellant cantidates for cancer markers as they represent response of the immune system. The generation of these autoantibodies in response to autologus cellular antigenes is not static and it is measurable by analyses. Autoantibodies are extremely stable in serum samples and are know to persist for extended times after removal of the antigenic factor. This is a distinct advantage for their use and are potential markers for detection of carcinoma in human fluids. Cancer antigens have limited half-life. Indeed, the stability of autoantibodies is imortant for development of laboratory tests. The main objective of autoantibodies discovery is to identify molecular markers capable of discriminating the „healthy“ state from the „disease“ state preferentially in the early asymptomatic stages. Biomarker screening test may enhance the diagnostic value of physical examination, medical tests or other procedures. Cancer screening procedures such as mammography or screening colonoscopy serve in finding initial signs of cancer. Different strategies have been developed in discovering biomarkers. The sensitivity and the sensibility of screening test must be high for the detection of the autoantibodies. Developing strategies for autoantibodies are needed. That may contribute to early cancer detection and improvement of therapy results.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:105:306758
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2016-08-08 07:30:28